Stella Pharma (TSE:4888) Debt-to-Equity : 0.36 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Pharma Debt-to-Equity?

Stella Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円160.0 Mil. Stella Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was 円813.3 Mil. Stella Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was 円2,671.2 Mil. Stella Pharma's debt to equity for the quarter that ended in Dec. 2023 was 0.36.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Stella Pharma's Debt-to-Equity or its related term are showing as below:

TSE:4888' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.36 Med: 0.41 Max: 6.13
Current: 0.36

During the past 5 years, the highest Debt-to-Equity Ratio of Stella Pharma was 6.13. The lowest was 0.36. And the median was 0.41.

TSE:4888's Debt-to-Equity is ranked worse than
67.92% of 1066 companies
in the Biotechnology industry
Industry Median: 0.145 vs TSE:4888: 0.36

Stella Pharma Debt-to-Equity Historical Data

The historical data trend for Stella Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Pharma Debt-to-Equity Chart

Stella Pharma Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-Equity

0.97

2.28

6.13

0.41

0.40

Stella Pharma Quarterly Data
	Mar19	Mar20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial										0.43	0.40	0.37	0.36	0.36

Competitive Comparison of Stella Pharma's Debt-to-Equity

For the Biotechnology subindustry, Stella Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Stella Pharma's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stella Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Stella Pharma's Debt-to-Equity falls into.

Stella Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Stella Pharma's Debt to Equity Ratio for the fiscal year that ended in Mar. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(160.008	+	933.3)	/	2752.501
	=	0.40

Stella Pharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(160.008	+	813.294)	/	2671.2
	=	0.36

Stella Pharma (TSE:4888) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Stella Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Stella Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Pharma (TSE:4888) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stella Pharma Corp (TSE:4888) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043

Website

https://stella-pharma.co.jp

Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.

Stella Pharma (TSE:4888) Headlines

No Headlines